13G Filing: Great Point Partners and PTC Therapeutics Inc. (PTCT)

Page 2 of 10

Page 2 of 10 – SEC Filing

CUSIP
No.
69366J200
13G Page
2 of 9 Pages
1.

NAMES OF REPORTING PERSONS

Great Point Partners, LLC

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

37-1475292

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
3. SEC USE ONLY
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

USA

NUMBER OF SHARES

BENEFICIALLY

OWNED BY EACH

REPORTING PERSON

WITH
5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

2,160,0001

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

2,160,0001

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,160,0001

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES
(See Instructions)

o
11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.24%2

12.

TYPE OF REPORTING PERSON (See Instructions)

IA

1 Includes options exercisable on or before December 15, 2017 to purchase 260,000 shares at an exercise price of $18 per share; provided that the filing of this Schedule 13G shall not be deemed to be an admission that any reporting person beneficially owns the shares underlying such options.
2 Based on a total of 41,244,004 shares outstanding, as reported by the Issuer on a Form 10Q filed with the SEC on May 5, 2017.

Follow Ptc Therapeutics Inc. (NASDAQ:PTCT)

Page 2 of 10